Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic

<b>Background</b>: The global COVID-19 pandemic has resulted in approximately 7 million deaths and a historic vaccination effort, with over 13.6 billion doses administered. Despite this, understanding of immune responses in vulnerable populations, such as transplant recipients (TR) and h...

Full description

Saved in:
Bibliographic Details
Main Authors: Lisette Alcantara Sanchez, Eloy Alvarez Guerra, Dongmei Li, Samantha M. King, Shannon P. Hilchey, Qian Zhou, Stephen Dewhurst, Kevin Fiscella, Martin S. Zand
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/12/12/1312
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846102532772855808
author Lisette Alcantara Sanchez
Eloy Alvarez Guerra
Dongmei Li
Samantha M. King
Shannon P. Hilchey
Qian Zhou
Stephen Dewhurst
Kevin Fiscella
Martin S. Zand
author_facet Lisette Alcantara Sanchez
Eloy Alvarez Guerra
Dongmei Li
Samantha M. King
Shannon P. Hilchey
Qian Zhou
Stephen Dewhurst
Kevin Fiscella
Martin S. Zand
author_sort Lisette Alcantara Sanchez
collection DOAJ
description <b>Background</b>: The global COVID-19 pandemic has resulted in approximately 7 million deaths and a historic vaccination effort, with over 13.6 billion doses administered. Despite this, understanding of immune responses in vulnerable populations, such as transplant recipients (TR) and hemodialysis patients (HD), remains limited, especially outside the US and Europe. <b>Methods</b>: To address this gap, we analyzed blood samples and deidentified data from the Instituto Nacional de Coordinación de Trasplante (INCORT) in The Dominican Republic, measuring antibody levels to SARS-CoV-2 post-infection and vaccination with BNT162b2 (Pfizer-BioNTech) and Sinovac-CoronaVac (Sinovac) in TR, HD, and healthy controls (CO). Using a fluorescent multiplex assay (mPlex-CoV) and mixed-effects modeling, we assessed variations in anti-S, anti-RBD, and anti-N IgG antibodies. <b>Results</b>: The results indicate that the CO group experienced an early peak in anti-S and anti-RBD antibodies, followed by stabilization. In contrast, the TR and HD groups showed a slower, gradual increase in antibodies. Despite fluctuations in the HD group, both the TR and HD groups maintained high anti-S and anti-RBD IgG levels, indicating a back-boosting effect from vaccination. However, elevated anti-N IgG levels in the TR and HD groups suggest potential reinfections. Additionally, prior SARS-CoV-2 infection led to higher anti-S IgG levels, with BNT162b2 associated with higher anti-S IgG and CoronaVac associated with higher anti-N IgG levels. <b>Conclusion</b>: These findings highlight the variability in antibody responses and the need for targeted public health strategies to diverse immunological profiles.
format Article
id doaj-art-eaf9d0039a5b48799feb677935a78733
institution Kabale University
issn 2076-393X
language English
publishDate 2024-11-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj-art-eaf9d0039a5b48799feb677935a787332024-12-27T14:57:49ZengMDPI AGVaccines2076-393X2024-11-011212131210.3390/vaccines12121312Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican RepublicLisette Alcantara Sanchez0Eloy Alvarez Guerra1Dongmei Li2Samantha M. King3Shannon P. Hilchey4Qian Zhou5Stephen Dewhurst6Kevin Fiscella7Martin S. Zand8Clinical and Translational Science Institute, University of Rochester, Rochester, NY 14642, USAInstituto Nacional de Coordinación de Trasplante, Instituto de Medicina Tropical y Salud Global, Universidad Iberoamericana, Santo Domingo 01219, Dominican RepublicClinical and Translational Science Institute, University of Rochester, Rochester, NY 14642, USADepartment of Medicine, Division of Nephrology, University of Rochester, Rochester, NY 14642, USADepartment of Medicine, Division of Nephrology, University of Rochester, Rochester, NY 14642, USADepartment of Medicine, Division of Nephrology, University of Rochester, Rochester, NY 14642, USADepartment Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USADepartment of Family Medicine, University of Rochester, Rochester, NY 14642, USAClinical and Translational Science Institute, University of Rochester, Rochester, NY 14642, USA<b>Background</b>: The global COVID-19 pandemic has resulted in approximately 7 million deaths and a historic vaccination effort, with over 13.6 billion doses administered. Despite this, understanding of immune responses in vulnerable populations, such as transplant recipients (TR) and hemodialysis patients (HD), remains limited, especially outside the US and Europe. <b>Methods</b>: To address this gap, we analyzed blood samples and deidentified data from the Instituto Nacional de Coordinación de Trasplante (INCORT) in The Dominican Republic, measuring antibody levels to SARS-CoV-2 post-infection and vaccination with BNT162b2 (Pfizer-BioNTech) and Sinovac-CoronaVac (Sinovac) in TR, HD, and healthy controls (CO). Using a fluorescent multiplex assay (mPlex-CoV) and mixed-effects modeling, we assessed variations in anti-S, anti-RBD, and anti-N IgG antibodies. <b>Results</b>: The results indicate that the CO group experienced an early peak in anti-S and anti-RBD antibodies, followed by stabilization. In contrast, the TR and HD groups showed a slower, gradual increase in antibodies. Despite fluctuations in the HD group, both the TR and HD groups maintained high anti-S and anti-RBD IgG levels, indicating a back-boosting effect from vaccination. However, elevated anti-N IgG levels in the TR and HD groups suggest potential reinfections. Additionally, prior SARS-CoV-2 infection led to higher anti-S IgG levels, with BNT162b2 associated with higher anti-S IgG and CoronaVac associated with higher anti-N IgG levels. <b>Conclusion</b>: These findings highlight the variability in antibody responses and the need for targeted public health strategies to diverse immunological profiles.https://www.mdpi.com/2076-393X/12/12/1312COVID-19SARS-CoV-2 vaccinetransplant recipientshemodialysisimmunocompromisedantibody response
spellingShingle Lisette Alcantara Sanchez
Eloy Alvarez Guerra
Dongmei Li
Samantha M. King
Shannon P. Hilchey
Qian Zhou
Stephen Dewhurst
Kevin Fiscella
Martin S. Zand
Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
Vaccines
COVID-19
SARS-CoV-2 vaccine
transplant recipients
hemodialysis
immunocompromised
antibody response
title Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
title_full Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
title_fullStr Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
title_full_unstemmed Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
title_short Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic
title_sort antibody response to sars cov 2 vaccines in transplant recipients and hemodialysis patients data from the dominican republic
topic COVID-19
SARS-CoV-2 vaccine
transplant recipients
hemodialysis
immunocompromised
antibody response
url https://www.mdpi.com/2076-393X/12/12/1312
work_keys_str_mv AT lisettealcantarasanchez antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT eloyalvarezguerra antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT dongmeili antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT samanthamking antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT shannonphilchey antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT qianzhou antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT stephendewhurst antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT kevinfiscella antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic
AT martinszand antibodyresponsetosarscov2vaccinesintransplantrecipientsandhemodialysispatientsdatafromthedominicanrepublic